Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy […]
3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »
For me, this was another week of heavy grant writing but also taking on Google again. How? Over how badly its search engine often performs on stem cell queries. I have a new piece at MedPage Today. It’s focused on the problem of Google Search promoting unproven stem cell clinic websites. Google still prefers stem
Weekly reads: Google, CIRM, young Swedish bone marrow Read More »
What’s more important than Woolly Mammoth de-extinction research in the stem cell arena? Only maybe a 10,000 other things. Still, the mammoth de-extinction efforts capture people’s attention much more than the average research story. Mammoth De-extinction update Is de-extinction only a pipette dream? This startup has a big, expensive plan to find out, Popular Science.
Paolo Macchiarini is one of a small group of people in the stem cell universe whose misconduct has blown up in the press. Piero Anversa, Haruko Obokata, Hwang Woo-Suk, and some operators in the unproven stem cell clinic sphere come to mind. Macchiarini published quite a few seriously problematic papers, some of which just hung
Weekly reads: late Macchiarini retractions, stem cells & Lululemon Read More »
There’s been much discussion about issues related to stem cells in the reproductive space such as human embryo models and differentiating stem cells into gametes, but there’s also interest in stem cell-assisted IVF. In this kind of method, stem cells are employed to make tissue cells such as ovarian stromal cells to support production of
Weekly reads: stem cell-assisted IVF, Takeda MSC trial, reporters getting stem cells Read More »
Most of us have heard of organoids but what about the related model called an “assembloid”, which is a term growing in use including from organoid researcher Sergiu Pasca of Stanford? Before we jump into that, be sure to enter The Niche stem cell image contest for your chance to win $100 or some swag.
Once every year or two here on The Niche I run contests for best pictures or videos. Today’s new contest is for the best stem cell research pictures. Most often what people send in as entries are microscopy images, but you can use your imagination. Today is a fitting day to launch the contest as
The Niche 2023 stem cell picture contest: $100 or swag Read More »
People often ask me what are the most promising stem cell therapies in development and new data suggest we should add stem cells for epilepsy to the list based on work by Neurona Therapeutics. I’ll start off the weekly recommended reads with this new mouse paper on cell therapy for epilepsy. Neurona Therapeutics: stem cells
I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over
Many of us first became aware of Vivek Ramaswamy as a Republican candidate for President. He was most well-known before that as a biotech leader. Given that biotech background, I decided to learn more about him. Surprisingly, his biomedical efforts may have started with embryonic stem cells. That caught my attention. This was way back
Vivek Ramaswamy & his surprising stem cell start Read More »